|Trade names||Otosporin, Cortisporin, others|
|Ear drop, ear drop|
|Defined daily dose||not established|
|AHFS/Drugs.com||FDA Professional Drug Information|
Neomycin/polymyxin B/hydrocortisone, sold under the brand Otosporin among others, is a medication used to treat otitis externa (swimmer's ear) and certain eye disorders. It consists of the antibiotics neomycin and polymyxin B, and the steroid hydrocortisone. It is used as an ear drop or eye drop.
The most common side effects include itchiness and a skin rash. Other side effects may include dizziness, hives, anaphylaxis, hearing loss, and headache. Safety in pregnancy and breastfeeding is unclear. The antibiotics work by killing specific types of bacteria while the steroids work by decreasing inflammation.
The combination was approved for medical use in the United States in 1964. In the United Kingdom a 10 ml bottle costs the NHS about £7.45 as of 2019. In the United States the wholesale cost of this amount is about US$50. In 2017, it was the 304th most commonly prescribed medication in the United States, with more than one million prescriptions.
Cortisporin was developed by Glaxo Wellcome and was approved by the Food and Drug Administration in 1975. In 1997, the rights were sold to Monarch Pharmaceuticals, a division of King Pharmaceuticals. In 2007, King sold it to JHP Pharmaceuticals. Par Pharmaceutical acquired JHP in 2014. In 2015, Endo International purchased Par.
Society and culture
In David Lazarus' February 4, 2016 LA Times column, a pharmacist recalled a 10 milliliter vial of the drug selling for around $10 in the early 2010s. In 2015, the price was $100, and in 2016, it reportedly was selling for $195. A generic version is priced at $144. The drug is owned by Dublin, Ireland-based Endo International.
Generic name: neomycin sulfate, polymyxin B sulfate, and hydrocortisone
Dosage form: otic suspension (liquid with ear dropper)
Generic name: neomycin sulfate, polymyxin B sulfate, bacitracin zinc and hydrocortisone
Dosage form: Dermatological ointment, drops
- "Hydrocortisone / neomycin / polymyxin b otic Use During Pregnancy". Drugs.com. Retrieved 19 April 2019. CS1 maint: discouraged parameter (link)
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 9 September 2020. CS1 maint: discouraged parameter (link)
- British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1164. ISBN 9780857113382.
- "Neomycin, Polymyxin B, Hydrocortisone Ophthalmic Suspension - FDA prescribing information, side effects and uses". Drugs.com. Retrieved 19 April 2019. CS1 maint: discouraged parameter (link)
- "Hydrocortisone/neomycin/polymyxin b otic Side Effects in Detail". Drugs.com. Retrieved 19 April 2019. CS1 maint: discouraged parameter (link)
- "DailyMed - neomycin sulfate, polymyxin b sulfate and hydrocortisone solution". dailymed.nlm.nih.gov. Retrieved 19 April 2019. CS1 maint: discouraged parameter (link)
- "NADAC as of 2019-02-27". Centers for Medicare and Medicaid Services. Retrieved 3 March 2019. CS1 maint: discouraged parameter (link)
- "Neomycin; Polymyxin B; Hydrocortisone - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.
- Lazarus, David (2016-02-04). "Martin Shkreli isn't alone in ripping off patients with crazy drug prices". latimes.com. Retrieved 2016-02-05. CS1 maint: discouraged parameter (link)